Dyne Therapeutics Inc. (DYN)
Dyne Therapeutics Inc. (DYN) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | 18.81 |
| Capitalización de mercado | 4.86B |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -519.4M |
| Beta | 1.08 |
| EPS (TTM) | -3.26 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -7.78 |
| P/B (TTM) | 6.13 |
| P/S (TTM) | n/a |
| Earnings Date | Nov 5, 2026 |
| Precio de venta | 32.76 |
| Volumen | 1,900,730 |
| Volumen medio (20D) | 2,231,791 |
| Abierto | 25.88 |
| Anterior Cerrar | 26.15 |
| Rango del día | 25.46 - 26.31 |
| Rango de 52 semanas | 11.64 - 27.30 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de DYN
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases usin...
Desempeño financiero
En 2025, los ingresos de Dyne Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -446.21M, un aumento de 40.58%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
3 semanas hace · Simply Wall St.
Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?Dyne Therapeutics (DYN) is back in focus after pricing an upsized follow on equity offering of 18,300,000 common shares at $20.50 each, raising about $375 million in gross proceeds. See our latest ana...
